IEQ Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

IEQ Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$1.07M	–	978
2023 Q1	$1.07M	Hold	10,000	–	–	0.02%	368
2022 Q4	$1.1M	Sell	10,000 -5,446	-35%	-$353K	0.03%	349
2022 Q3	$911K	Buy	15,446 +5,446	+54%	+$249K	0.03%	384
2022 Q2	$282K	Hold	10,000	–	–	0.01%	622
2022 Q1	$378K	Hold	10,000	–	–	0.01%	579
2021 Q4	$395K	Buy	+10,000	New	+$313K	0.01%	518

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

IEQ Capital's RXDX Position: Q2 2023 in Review

IEQ Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 10,000 shares — an estimated $1.07M sold.

IEQ Capital first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $1.1M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

IEQ Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
IEQ Capital sold 10,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.07M.
IEQ Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
IEQ Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $1.1M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on IEQ Capital's 13F filing for Q2 2023, filed 8 Aug 2023.